1
Application seeks reduced infusion frequency to support patient flexibility
Eisai Europe and Biogen Idec have announced the validation of a Marketing Authorisation Variation by the Medicines and Healthcare products Regulatory Agency (MHRA) for lecanemab – marketed as Leqembi®, in the UK.
The proposal aims to reduce the intravenous (IV) dosing frequency from every two weeks to every four weeks, following the initial 18-month treatment period at the approved fortnightly dose. This could provide greater flexibility for eligible adult patients with early Alzheimer’s disease (AD) and their…